Eisai Accelerates Progress in Oncology Research with New Data at ESMO Congress 2024, Including First Interim Analysis Results from the Phase 3 LEAP-012 Trial

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Source:
    PR Newswire (USA), September 4, 2024, 17pp
  • Additional Information
    • Abstract:
      Late-breaking results from the Phase 3 LEAP-012 trial offer further insight into the treatment of patients with unresectable, non-metastatic hepatocellular carcinoma (HCC); data are selected for ESMO Presidential Symposium Session Additional presentations in HCC, differentiated thyroid cancer, breast cancer, endometrial carcinoma and non-small cell lung cancer highlight Eisai's commitment to advancing care across multiple tumor types NUTLEY, N.J., Sept...